MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

Rhea-AI Summary

MetaVia (Nasdaq: MTVA) announced that data from its Phase 2a clinical trial of DA-1241, a novel GPR119 agonist, will be presented as a late-breaking poster at the EASL Congress 2025 in Amsterdam (May 7-10, 2025). The presentation will focus on the drug's hepatoprotective and glucose-regulating effects in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH) from a 16-week randomized placebo-controlled trial.

The presentation titled 'DA-1241, a GPR119 Agonist, Demonstrates Hepatoprotective and Glucose-Regulating Effects in a 16-week Randomized Placebo-Controlled Trial in Presumed MASH Patients' will be delivered by Dr. Rohit Loomba from the University of California, San Diego. The poster will be available on MetaVia's website following the presentation.

CAMBRIDGE, Mass., April 23, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from its Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH), has been accepted as a late-breaking poster presentation at the European Association for the Study of the Liver (EASL) Congress 2025, taking place May 7-10, 2025 in Amsterdam, the Netherlands.

• Title: DA-1241, a GPR119 Agonist, Demonstrates Hepatoprotective and Glucose-Regulating Effects in a 16-week Randomized Placebo-Controlled Trial in Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients
• Presenting Author: Rohit Loomba, MD, MHSc, Professor of Medicine in the Division of Gastroenterology, and Adjunct Professor in the Division of Epidemiology at University of California, San Diego.
• Abstract Number: LB2517
• Final Abstract ID: LBP-005
• Session: Late Breaker Posters
• Session Date: May 7-10, 2025
• Presentation Start: May 7, 2025, 8:30 am CET

A copy of the poster will be available on the Posters section of the MetaVia website after the presentation.

About DA-1241
DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes (T2D). Agonism of GPR119 in the gut promotes the release of key gut peptides GLP-1, GIP, and PYY. These peptides play a further role in glucose metabolism, lipid metabolism and weight loss. DA-1241 has beneficial effects on glucose, lipid profile and liver inflammation, supported by potential efficacy demonstrated during in vivo preclinical studies. The therapeutic potential of DA-1241 has been demonstrated in multiple pre-clinical animal models of MASH and T2D where DA-1241 reduced hepatic steatosis, inflammation, fibrosis, and improved glucose control. Furthermore, in Phase 1a, 1b and 2a trials, DA-1241 was well tolerated in both healthy volunteers and those with T2DM. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.

About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.

For more information, please visit www.metaviatx.com.

Contacts:

MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-announces-late-breaking-poster-presentation-on-da-1241-at-the-easl-congress-2025-302435642.html

SOURCE MetaVia Inc.

FAQ

What are the key findings of MetaVia's (MTVA) Phase 2a trial for DA-1241 in MASH patients?

The Phase 2a trial investigated DA-1241's hepatoprotective and glucose-regulating effects in MASH patients over 16 weeks. Detailed results will be presented at EASL Congress 2025.

When will MetaVia (MTVA) present its DA-1241 clinical trial results at EASL 2025?

MetaVia will present the DA-1241 trial results on May 7, 2025, at 8:30 am CET during the Late Breaker Posters session at EASL Congress 2025 in Amsterdam.

What is the mechanism of action of MetaVia's (MTVA) DA-1241 drug?

DA-1241 is a G-Protein-Coupled Receptor 119 (GPR119) agonist designed to treat metabolic dysfunction-associated steatohepatitis (MASH).

Where can investors find MetaVia's (MTVA) EASL 2025 poster presentation materials?

The poster presentation will be available in the Posters section of MetaVia's website after the May 7, 2025 presentation.